Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06150781

Aimovig Pregnancy Exposure Registry

Sponsor: Amgen

View on ClinicalTrials.gov

Summary

The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.

Official title: GENESIS: AIMOVIG® Pregnancy Exposure Registry

Key Details

Gender

FEMALE

Age Range

18 Years - 99 Years

Study Type

OBSERVATIONAL

Enrollment

2842

Start Date

2021-01-27

Completion Date

2027-10-28

Last Updated

2025-11-04

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

erenumab-aooe

Dose and treatment duration will be advised by the HCP

Locations (1)

IQVIA Virtual Site

Durham, North Carolina, United States